Primary Record
valsartan
- In stock
- 1,169 g
- Purity
- 98.8 %
- CAS
- 137862-53-4
Compound Identifiers & Properties
- CAS
- 137862-53-4
- PubChem CID
- 60846
- SMILES
- CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O
- Canonical SMILES
- CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C
Names & Synonyms
- valsartan
- Diovan
- 137862-53-4
- Tareg
- Provas
- Exforge
- Nisis
- Prexxartan
- Kalpress
- Miten
- Vals
- ent-Valsartan
- walsartan
- L-Valsartan
- Valsarran
- Valzaar
- Valtan
- cardopan
- valsartanin
- valsartanum
- Diovan Hct
- Valpression
- Valsartana
- Valsaltan
- Varexan
- [3H]valsartan
- Mixture Name
- CGP 48933
- Valsartan RS
- Valsartan CRS
- Valtan;
- Diovan (TN)
- Diovan, Valsartan
- valsartan (Diovan)
- Valsartan [USAN:INN]
- Valzaar (TN)
- Valtan (TN)
- CGP-48933
- Valsartan (Standard)
- CEPA brand of valsartan
- Lacer brand of valsartan
- Sanol brand of valsartan
- Esteve brand of valsartan
- RefChem:6344
- Aventis brand of valsartan
- Schwarz brand of valsartan
- Spectrum_001796
- VALSARTAN [INN]
- VALSARTAN [JAN]
- Novartis brand of valsartan
- VALSARTAN [MI]
- MFCD00865840
- AC1Q5QIK
- VALSARTAN [HSDB]
- VALSARTAN [USAN]
- Spectrum2_001120
- Spectrum3_001831
- Spectrum4_000749
- Spectrum5_001582
- 80M03YXJ7I
- CHEMBL1069
- UNII-80M03YXJ7I
- VALSARTAN [VANDF]
- C24H29N5O3
- D04HSR
- D06UDG
- Prexxartan (oral solution)
- VALSARTAN [MART.]
- AC1L1U1M
- SCHEMBL2542
- VALSARTAN [USP-RS]
- VALSARTAN [WHO-DD]
- CHEBI:9927
- BSPBio_003501
- DTXSID6023735
- GTPL593
- KBioGR_001078
- KBioSS_002289
- Valsartan (1708762)
- VALSARTAN [EMA EPAR]
- DAFIRO COMPONENT VALSARTAN
- HSDB 7519
- MLS000759423
- MLS001424088
- Valsartan (JAN/USAN/INN)
- BIDD:GT0345
- NSC-758927
- SCHEMBL678231
- SPECTRUM1505209
- SPBio_001260
- Valsartan - Bio-X trade mark
- COPALIA COMPONENT VALSARTAN
- EXFORGE COMPONENT VALSARTAN
- IMPRIDA COMPONENT VALSARTAN
- Valsartan (JP18/USP/INN)
- Valsartan [USAN:USP:INN:BAN]
- ENTRESTO COMPONENT VALSARTAN
- GTPL3937
- orb1300528
- VALTURNA COMPONENT VALSARTAN
- VALSARTAN [EP IMPURITY]
- VALSARTAN [ORANGE BOOK]
- SCHEMBL29406387
- VALSARTAN [EP MONOGRAPH]
- Valsartan, >=98% (HPLC)
- ERK5-3M18
- KBio2_002287
- KBio2_004855
- KBio2_007423
- KBio3_003006
- KS-00000ISS
- C09CA03
- EZR-104
- VAL-489
- VALSARTAN [USP MONOGRAPH]
- (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
- ACWBQPMHZXGDFX-QFIPXVFZSA-N
- DAFIRO-HCT COMPONENT VALSARTAN
- COPALIA-HCT COMPONENT VALSARTAN
- DTXCID801508574
- GLXC-05207
- HMS1922L21
- HMS2051L12
- HMS2093K22
- HMS2232F05
- HMS3651E04
- HMS3715P12
- IMPRIDA-HCT COMPONENT VALSARTAN
- Pharmakon1600-01505209
- 48933, CGP
- ACT02671
- ALBB-038653
- BCP05184
- CGP48933
- CID60846
- MSK10065
- ZINC3875259
- AGSAV301 COMPONENT VALSARTAN
- ANW-49040
- BDBM50049186
- CID:60846
- EBC-11260
- HY-18204R
- NP2632
- NSC758927
- s1894
- Valsartan for system suitability CRS
- DIOVAN HCT COMPONENT VALSARTAN
- N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
- Valsartan for peak identification CRS
- AKOS015914315
- AKOS015994698
- C24-H29-N5-O3
- EXFORGE HCT COMPONENT VALSARTAN
- (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
- AC-4543
- AM90287
- AN-7255
- CB10988
- CCG-101028
- CCG-221275
- CS-1967
- DB00177
- DS-1248
- FV28662
- KS-1194
- NC00278
- NSC 758927
- RTR-031794
- VA11929
- NCGC00178027-08
- NCGC00178027-11
- NCGC00178027-19
- 137863-60-6
- BC204156
- BR-58790
- BV164506
- CPD000466318
- HY-18204
- I997
- L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
- SAM001246581
- SC-00971
- SMR000466318
- EC 604-045-2
- SBI-0206738.P001
- SID:283537531
- AB0013966
- AB2000354
- J550.722G
- LS-161334
- ST2408288
- TL8000869
- TR-031794
- B2214
- FT-0631156
- FT-0675772
- SW197658-2
- V-120
- V0112
- N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
- 4997-EP2270011A1
- 4997-EP2272841A1
- 4997-EP2277879A1
- 4997-EP2295406A1
- 4997-EP2295422A2
- 4997-EP2298772A1
- 4997-EP2298776A1
- 4997-EP2298779A1
- 4997-EP2301923A1
- 4997-EP2301931A1
- 4997-EP2301936A1
- 4997-EP2305219A1
- 4997-EP2308562A2
- 4997-EP2308839A1
- 62V534
- D00400
- J10013
- N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
- S-6418
- AB00639940-06
- AB00639940-08
- AB00639940_09
- AB00639940_11
- EN300-6482022
- A807313
- C081489
- F036602
- L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
- Q155472
- SR-05000001928
- SR-05000001928-1
- Valsartan for Peak Identification CRS (Y0001131)
- Valsartan for System Suitability CRS (Y0001145)
- (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
- BRD-K45158365-001-02-3
- BRD-K45158365-001-05-6
- BRD-K45158365-001-10-6
- BRD-K45158365-001-11-4
- I14-41498
- N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
- 137862-87-4
- D000068756
- N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
- Z1379303659
- Valsartan Working Standard (Secondary Reference Standard)
- Valsartan, European Pharmacopoeia (EP) Reference Standard
- N-[4-[2-(1H-Tetrazol-5-yl)phenyl]benzyl]-N-valeryl-L-valine
- N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine
- Valsartan, United States Pharmacopeia (USP) Reference Standard
- (2S)-3-Methyl-2-(pentanoyl{[2?-(1H-tetrazol-5-yl)-4-biphenylyl]methyl}amino)butanoic acid
- (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
- N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine
- N-(1-OXOPENTYL)-N-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-L-VALINE
- N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine
- (-)-N-Pentanoyl-N-[2 -(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine
- (2~{S})-3-methyl-2-[pentanoyl-[[4-[2-(2~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
- (2S)-3-methyl-2-(N-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}pentanamido)butanoic acid
- (2S)-3-Methyl-2-(pentanoyl-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)amino)butanoic acid
- (S)-N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl)-valine
- N-(1-Oxopentyl)-N-[4-[2-(1H-tetrazol-5-yl)phenyl]benzyl]-L-valine
- N-[4-[2-(1H-Tetrazol-5-yl)phenyl]benzyl]-N-(1-oxopentyl)-L-valine
- N-pentanoyl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-L-valine
- N-Pentanoyl-N-[2 -(1H-tetrazol-5-yl)-4-biphenylylmethyl]-L-valine
- N-Valeryl-N-[[2 -(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-L-valine
- Valsartan, Pharmaceutical Secondary Standard; Certified Reference Material
- (2S)-3-Methyl-2-(N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)butanoic acid
- (2S)-N-Valeryl-N-[2 -(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-2-isopropylglycine
- (5)-2-{N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]pentanamido}-3-methylbutanoic acid
- (S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
- 3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-butanoic acid
- 3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-yl]-amino}-butyric acid
- L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]-
- L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI)
- L-Valine,N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]- (9CI)
- L-Valine,N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]-(9ci)
- L-Valine,N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
- N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-3-yl)methyl)-N-pentanoyl-L-valine
- N-(1-Oxopentyl)-N-[[2 -(2H-tetrazol-5-yl)-4-biphenylyl]methyl]-L-valine
- N-(1-oxopentyl)-N-[[2'-(1h-tetrazol-5-yl) [1,1'-bi-phenyl]-4-yl]methyl]-l-valine
- N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(L)-valine
- N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-L-valine
- Valsartan for peak identification, European Pharmacopoeia (EP) Reference Standard
- Valsartan for system suitability, European Pharmacopoeia (EP) Reference Standard
- Valsartan, 99%, a nonpeptide angiotensin II AT1 receptor antagonist - 250MG 250mg
- (2R)-3-Methyl-2-[pentanoyl[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]amino]butanoic Acid (Valsartan (R)-Enantiomer)
- (2S)-3-Methyl-2-(N-((2'-(1H-1,2,3,4-tetrazol-5-yl)-(1,1-biphenyl)-4-yl)methyl)pentanamido)butanoic acid
- (2S)-3-methyl-2-(N-((4-(2-(2H-1,2,3,4-tetrazol-5-yl)phenyl)phenyl)methyl)pentanamido)butanoic acid
- (2S)-3-methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
- (2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
- (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid.
- (2S)-3-Methyl-2-{N-pentanoyl-N'-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butanoic acid
- (2S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
- (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoicacid
- (S)-2-(N-((2'-(1H-Tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
- (S)-2-(N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
- (S)-2-[[[2 -(1H-Tetrazole-5-yl)-1,1 -biphenyl-4-yl]methyl](pentanoyl)amino]-3-methylbutanoic acid
- (s)-3-methyl-2-[N-({4-[2-(2h-1,2,3,4-tetrazol-5-yl) phenyl]phenyl}methyl)pentanamido]butanoic acid
- (S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
- (s)-3-methyl-2-{pentanoyl-[-2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
- (S)-3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
- (S)-3-Methyl-2-{pentanoyl-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
- (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine
- (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amine
- (S)-N-(1-Carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
- 2-{[2''-(2,3-Dihydro-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-pentanoyl-amino}-3-methyl-butyric acid
- 3-Methyl-2-{((S)-pentanoyl)-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
- 943333-68-4
- CGP48933, CGP-48933, CGP 48933, Valsartan, Diovan, Miten, Nisis, Prova, Tareg, Vals, Walsartan
- L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; (S)-2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
- L-VALINE,N-(1-OXOPENTYL)-N-[[2''-(1H-TETRAZOL-5-YL)[1,1''-BIPHENYL]-3-YL]METHYL]-
- U35
- Valsartan; (2S)-3-Methyl-2-[pentanoyl[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]amino]butanoic acid; L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI); N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine; CGP 48933; Cardopan; Diovan; Nisis; Tareg; Valsarect; Valsartanin